Why Abzena?
Our focused approach.
Developing an efficient, scalable, validated, and cost-effective manufacturing process is essential for success in today’s competitive biologics markets.
Whether you need assistance developing a new process, are improving existing processes, or are preparing to manufacture your product, you will benefit from our in-depth expertise.
Through a comprehensive technology transfer program, we deliver a successful scale-up model to ensure a robust and consistent manufacturing process from clinical to commercial scale.
We collaborate with your team to de-risk the pathway to commercialization, ensure manufacturability, and deliver a quality biologic medicine to the patient.
Abzena has established a robust, end-to-end manufacturing platform in our San Diego, CA facility that is meticulously designed to produce high-quality biologic drug substance for clinical and commercial use. From the initial thaw of a master cell bank (MCB) to the final bulk drug substance, each unit operation is carried out under strict cGMP conditions.
Interested in learning more about our fully integrated development and manufacturing capabilities for biologics? Get in touch with our experts today.
At Abzena, we’ve continued to invest and build out Clinical & Commercial Manufacturing capabilities at our dedicated cGMP facility in San Diego, CA. Our facility has been designed to deliver high-quality recombinant proteins and antibodies at scales up to 2000 L, incorporating single-use bioreactors and two standalone production trains to safeguard product quality. By combining our deep scientific expertise, a robust Quality Management System (QMS), and flexible capacity, Abzena provides the integrated support needed to progress seamlessly from clinical batches to full-scale commercial production.
Learn more by downloading our latest info sheet.
To help promote innovation and continuous improvement Abzena has a framework following the ICH guidance ‘Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management’. Working collaboratively alongside you, this will support the management of post approval Chemistry and Manufacturing Control (CMC) changes for your product. We use a scientific and risk-based approach to inform your decision making, ensuring that post approval changes are fit for purpose. Our team are experienced in creating robust data packages that help facilitate regulatory review.
By combining a purpose-built cGMP facility, single-use disposable platforms, and rigorously validated processes, Abzena delivers a clear, scalable, and compliant pathway from cell bank to bulk drug substance.
Our end-to-end solution is structured to minimize risk, maximize quality, and help you successfully advance your biologic through clinical development and into the commercial market.
By using stage-appropriate and fit-for-purpose analytical methods for clinical manufacturing, we provide data-driven insights needed to refine and scale processes efficiently – minimizing risk, reducing rework, and positioning programs for future success. Abzena’s GMP manufacturing infrastructure uses validated release and stability methods to support clinical trial material production. Routine testing of critical quality attributes (CQAs) ensures each batch meets stringent regulatory standards throughout clinical development.
Abzena has extensive experience in cGMP and non-GMP production for recombinant proteins, antibodies and conjugates for preclinical, clinical and commercial materials. We have expertise in employing single-use technology allows for rapid turnaround times and cost-effective solutions. Our biologics manufacturing facilities located in San Diego, CA, provides world-class cGMP manufacturing.
The leading biologics CDMO + CRO that accelerates drug development, moving medicine forward for patients in need.